This MedLibrary.org supplementary page on Takeda Pharmaceuticals is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
| Type | Public (TYO: 4502) |
|---|---|
| Founded | 1781 |
| Headquarters | Osaka, Japan |
| Key people | Kunio Takeda, Chairman Yasuchika Hasegawa, President |
| Industry | Pharmaceuticals |
| Revenue | ▲$10.360 billion USD (FY 2005) |
| Net income | ▲$2.677 billion USD (FY 2005) |
| Employees | 15,069 (2005) |
| Website | www.takeda.com |
Takeda Pharmaceutical Company Limited (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha?) (TYO: 4502) is the largest pharmaceutical company in Japan, with overseas business offices in Europe and in the United States. Their American subsidiary, Takeda Pharmaceuticals North America, Inc., is based in Deerfield, Illinois. Global research and development is split between Deerfield and London.
One of their mainstay drugs is Actos, a compound used in the treatment of certain types of diabetes.
Takeda also owns TAP Pharmaceuticals, a joint venture with Abbott Laboratories. The company has also licensed non-exclusively the RNAi technology platform developed by Alnylam, creating a potentially long-term partnership between the companies.[1]
In 2007, Takeda Pharmaceutical was awarded the Bad Product Award (2007 Overall Winner) by Consumers International[2]. The company advertises the sleeping pill Rozerem to children in its "Back to School"-campaign (“Rozerem would like to remind you that it’s back to school season. Ask your doctor today if Rozerem is right for you.”) The Jury's motivation was that the advertisement ran without noting the very serious side effects that this drug can have, including increased thoughts of suicide in already depressed patients. Takeda pharmaceuticals also failed to mention the precautions on its packaging about children using this drug.
References
- ^ staff (2008-06-15). "Takeda Signs On as Alnylam's Asian Partner for $150M Upfront" (print), Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., p. 14. Retrieved on 2008-07-06.
- ^ [1] Consumers International – Press briefing International Bad Product Awards 2007
External links
 This article about a Japanese corporation- or company-related topic is a stub. You can help Wikipedia by expanding it. |
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 18 September 2008, at 20:50.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Takeda Pharmaceuticals".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.